超声乳化白内障摘除治疗晶状体溶解性青光眼的临床效果

目的:探讨超声乳化白内障摘除治疗晶状体溶解性青光眼的效果。方法:对25例晶状体溶解性青光眼患者控制眼压后行白内障摘除联合人工晶状体囊袋内植入术,观察术中、术后并发症,术后视力及眼压。结果:所有患者手术顺利,后囊完整,术后视力恢复好,眼压得到控制。所有患者无明显术中、术后并发症的发生。结论:超声乳化白内障摘除治疗晶状体溶解性青光眼安全有效。     

青光眼的中枢损伤

青光眼性损伤的形态学特征及病理机制 ,在视网膜节细胞水平及视神经水平已得到广泛研究 ;最近研究表明 ,青光眼对外侧膝状体、视皮质等中枢视路也存在相应损伤 ,并且提示青光眼的中枢损伤可能参与视功能状态的进一步恶化。我们对近年来青光眼中枢损伤的病理形态学及病理机制研究作一综述。     

眼眶海绵状血管瘤病理学机制研究

眼眶海绵状血管瘤 (orbitalcavernoushemangioma ,OCH)是一种常见的眶内良性肿瘤 ,由于眼眶海绵状血管瘤的大体形态与身体其他部位海绵状血管瘤不尽相同 ,长期以来对其发病机制说法不一。本文从包膜假说、细胞外基质假说、血管形成因子假说、雌激素调控假说、瘤腔缺氧假说等 5个方面分析其可能的发病机制。     

Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: Results from a five-year longitudinal assessment

The last international consensus conference about hepatitis C virus (HCV) treatment emphasized the importance of treatment for persons coinfected with HCV and human immunodeficiency virus (HIV). As liver biopsy precedes treatment, we aimed to identify factors associated with the performance of liver biopsy among HIV-HCV coinfected drug users during a 5-year follow-up to study their access to HCV treatment. Of the 296 patients followed in the HIV hospital departments of Nice and Marseilles and with retrievable records about HCV diagnosis and care, 166 were eligible for analysis having had detectable HCV RNA at least once during the study period. Overall, 45.2% of patients underwent liver biopsy during follow-up. Using proportional hazard models, predictors of having had a liver biopsy were high social support, complete abstinence from drug injection, and lack of immunosuppression as well as male gender, no history of multiple incarcerations, more recent onset of drug use, and an increase of liver enzyme levels. These results suggest that specific efforts should be devoted to HIV-HCV coinfected drug users to assist with stabilizing these patients to optimize their access to HCV care whenever possible. The MANIF 2000 study group includes C. Boirot, A. D. Bouhnik, M. P. Carrieri, J. P. Cassuto, M. Chesney, P. Dellamonica, P. Dujardin, S. Duran, J. G. Fuzibet, H. Gallais, J. A. Gastaut, G. Lepeu, D. A. Loundou, C. Marimoutou, D. Mechali, J. P. Moatti, J. Moreau, M. Nègre, Y. Obadia, I. Poizot-Martin, C. Pradier, D. Rey, C. Rouzioux, A. Sobel, B. Spire, F. Trémolières, and D. Vlahov.     

应用皮肤试验抑制指数评价阿伐斯汀的起效时间

目的皮肤试验抑制指数(Skin Test Inhibition Index,STII)是评价抗组胺药疗效的一个药效学指标,本试验以阿伐斯汀为例应用STII方法评价抗组胺药阿伐斯汀的起效时间。方法选择27例花粉症病人,分为阿伐斯汀组(24例)和安慰剂组(3例),并分别于服药前及服药30、90min后观察受试者的过敏原皮试反应,计算STII值,并将STII达到10的时间定为起效时间。结果安慰剂组前后过敏原皮试风团无显著差异,而阿伐斯汀组30、90min后,STII值分别为22.2、237.7。故可初步认为阿伐斯汀的起效时间小于30min。结论 STII可做为评价抗组胺药起效时间的客观指标之一。     

Guidelines for treatment of ulcerative colitis in children

This paper introduces the guidelines for treatment of ulcerative colitis in children, created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (Chair: Yuichiro Yamashiro) and the Japanese Society for Pediatric Inflammatory Bowel Disease (IBD) (Chair: Akio Kobayashi). The ideas of the working group, with regard to the fundamental differences in medical treatment between children and adults, included: (1) for children, intensive medical treatment including appropriate systemic management is important during the acute phase of illness. (2) Treatment with steroids, which can cause growth disturbances, should not be continued for long periods of time. (3) Pulsed steroid therapy, selective removal of blood cells, and intravenous infusion of cyclosporin should be included in the therapeutic option for severe and fluminant cases.